• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MaxCyte, Inc. - Common Stock (NQ:MXCT)

    1.015 +0.193 (+23.45%)
    Streaming Delayed Price Updated: 1:40 PM EDT, May 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about MaxCyte, Inc. - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Announces Planned CFO Transition in 2026
    Company initiates search for successor 
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
    MaxCyte’s Flow Electroporation® Technology will support efficient gene delivery to advance Moonlight Bio’s engineered T cell therapies 
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Signs Platform License Agreement with Adicet Bio
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
    MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapies 
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
    MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines 
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
    TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for... 
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)
    From Glancy Prongay & Murray LLP
    Via Business Wire
    News headline image
    MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Announces Retirement of Board Member Art Mandell
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
    Since 1999, MaxCyte’s non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects 
    From MaxCyte, Inc
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.